BI34 Lung toxicity with methotrexate: fact or fiction?

Adam Gold,Paul D Yesudian

DOI: https://doi.org/10.1093/bjd/ljae090.322

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract Methotrexate (MTX) is widely used as a first-line immunomodulator for inflammatory skin diseases. MTX-induced lung toxicity is a rarely reported complication, and its prevalence is unclear. We conducted a survey of UK clinicians on their experiences with MTX lung toxicity. In total, 109 clinicians, including 54 dermatologists (49.5%), 19 radiologists (17.4%), 26 respiratory physicians (23.9%) and 10 respondents not stating their specialty (9.2%), completed an online questionnaire that assessed their experiences with MTX-induced lung toxicity. A total of 12 questions were sent to clinicians across the UK from October 2023 to December 2023. Overall, 93 clinicians (85.3%) reported seeing either no cases (n = 58, 53.2%) or between 1 and 5 cases (n = 35, 32.1%) of MTX-induced lung toxicity. Of these, only four (3.7%) respondents identified MTX-induced lung changes in patients with dermatological indications, in the absence of other causes. One respondent did not answer the question of how many cases they had seen. In the subgroup of clinicians who observed more than 5 cases (n = 15, 13.8%), there were no dermatologists, and none reported MTX use for dermatological indications. All patients had rheumatological/connective tissue diseases (CTDs). Of those who reported seeing more than 5 cases, 10 (67%) were respiratory physicians and 5 (33%) were radiologists. Of those who reported seeing no cases of MTX-related lung changes, 41 (71%) were dermatologists. The main lung complications reported were pulmonary fibrosis and pneumonitis, with variable outcomes regarding improvement. In a 2009 literature review of 3463 patients with rheumatoid arthritis treated with MTX, 84 patients (2%) experienced some form of lung toxicity, with only 15 cases (0.4%) being attributed to MTX. In contrast, in 2015 a review of clinical trials involving patients with psoriasis, psoriatic arthritis or inflammatory bowel disease found no significant increase in respiratory adverse events for MTX users over treatment periods of 16–52 weeks. Of 1630 participants in 7 trials, only 1 MTX-treated patient developed pneumonitis (0.06%). These findings are reassuring and seem to suggest that lung toxicity is more commonly linked to CTD or other conditions rather than to MTX treatment for skin disease.

dermatology